Susquehanna International Group, LLP Cassava Sciences Inc Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$9.57 - $35.08 $9.45 Million - $34.7 Million	987,900 Added 229.1%	1,419,100 $41.8 Million
Q2 2024 Aug 15, 2024	BUY	$12.35 - $26.11 $3.57 Million - $7.54 Million	288,700 Added 202.6%	431,200 $5.33 Million
Q1 2024 May 07, 2024	SELL	$18.44 - $26.41 $4.42 Million - $6.33 Million	-239,700 Reduced 62.72%	142,500 $2.89 Million
Q4 2023 Feb 14, 2024	SELL	$12.64 - $30.11 $1.06 Million - $2.53 Million	-83,900 Reduced 18.0%	382,200 $8.6 Million
Q3 2023 Nov 14, 2023	BUY	$16.64 - $25.32 $2.79 Million - $4.24 Million	167,400 Added 56.04%	466,100 $7.76 Million
Q2 2023 Aug 11, 2023	SELL	$21.59 - $27.88 $237,490 - $306,680	-11,000 Reduced 3.55%	298,700 $7.32 Million
Q1 2023 May 16, 2023	SELL	$23.46 - $36.44 $8.25 Million - $12.8 Million	-351,500 Reduced 53.16%	309,700 $7.47 Million
Q4 2022 Feb 14, 2023	SELL	$27.82 - $44.16 $6.87 Million - $10.9 Million	-246,900 Reduced 27.19%	661,200 $19.5 Million
Q3 2022 Nov 14, 2022	BUY	$16.33 - $51.06 $3.49 Million - $10.9 Million	213,500 Added 30.74%	908,100 $38 Million

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $154M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.